Regeneron, Sanofi: FDA Approves Dupixent To Treat Adult Patients With Bullous Pemphigoid

The FDA has approved Regeneron and Sanofi's Dupixent for the treatment of bullous pemphigoid (BP) in adults, making it the only targeted medicine available for this rare skin disease. The approval was based on Phase 2/3 trial data demonstrating improvements in sustained disease remission, reduced itch, and decreased oral corticosteroid use compared to placebo; BP affects approximately 27,000 adults in the U.S. Dupixent is now approved to treat eight distinct diseases in the U.S. with underlying type 2 inflammation.

Analysis

Regeneron Pharmaceuticals Inc. (REGN) and Sanofi S.A. (SNY) have secured U.S. Food and Drug Administration (FDA) approval for Dupixent (dupilumab) to treat adult patients with bullous pemphigoid (BP), a chronic and debilitating rare skin disease. This regulatory milestone establishes Dupixent as the sole targeted medicine in the U.S. for BP, a condition affecting approximately 27,000 adults whose disease remains uncontrolled by systemic corticosteroids. The approval was predicated on positive ADEPT Phase 2/3 trial data, which demonstrated significant improvements in sustained disease remission, as well as reductions in itch and oral corticosteroid use compared to placebo. While common adverse events such as arthralgia, conjunctivitis, blurred vision, herpes viral infections, and keratitis were observed more frequently with Dupixent in the elderly population compared to placebo, the overall benefit-risk profile supported approval. This marks Dupixent's eighth U.S. approval for distinct diseases driven by type 2 inflammation, highlighting its expanding therapeutic reach. The development is viewed with strongly positive sentiment (sentiment score: 0.75) and a moderate market impact score (0.6), supported by strongly positive individual sentiment for both REGN and SNY (0.8), indicating optimism regarding this label expansion.

Key Decisions for Investors

• Investors should assess the incremental revenue opportunity for Regeneron and Sanofi presented by Dupixent's approval for bullous pemphigoid, particularly given its status as the only targeted therapy for this patient population of approximately 27,000 in the U.S.
• The successful expansion to an eighth indication reinforces Dupixent's blockbuster drug status and its role as a key growth driver for both companies; continued monitoring of its market penetration and competitive landscape across all indications is warranted.
• Consider this approval as a significant positive development for the Dupixent franchise, bolstering the investment thesis for REGN and SNY, while also acknowledging the reported adverse event profile within the specific patient population for a comprehensive risk assessment.